Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Quick Summary:

We remain focused on supporting physicians and hospitals with our diagnostic radiopharmaceuticals to help achieve better patient outcomes for traditional Medicare FFS beneficiaries.” About PYLARIFY® (piflufolastat F 18) InjectionPYLARIFY® (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis.Radiology.2020;296:44-55.doi:10.1148/radiol.2020191689.2Mena et al.18 F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889.doi: 10.2967/jnumed.119.234799.Epub 2019 Nov 1.3Alipour et al.

Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol.2019; 11: 1758835919876828.4Werner et al 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging Theranostics 2020; 10(1):1-16.doi:10.7150/thno.37894.5Petersen LJ, Zacho HD.

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Lantheus Holdings, Inc.

Category: Technology

Markets: ChinaCanadaMaliSweden

Topics: Nasdaq:LNTH US5165441032

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-04 @ 12:30:00 (1 days ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 1150 words

Reading Time: 7 minutes read

Sentences: 43 lines

Sentence Length: 27 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 23395727

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 42 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 8 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions